Fagron NV (ENXTBR: FAGR)
Health Care · Health Care Providers & Services · BE
€22.40
+0.90% today · +8.8% 1Y
Fagron NV (ENXTBR: FAGR) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $1.82B and employs 4,880 people.
Over the last twelve months the share price has gained 8.8%, trading between 19.84 and 25.30.
Tweenvest scores Fagron NV across four factors: quality 84/100, value 66/100, growth 68/100, dividend 76/100. Its strongest factor is quality.
FAGR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.82B
- Revenue (TTM)
- $1.18B
- P/E
- 17.76
- EPS
- 1.25
- Dividend yield
- 1.79%
- Beta (5Y)
- 0.35
- 52-week high
- €25.30
- 52-week low
- €19.84
- Avg volume (3M)
- —
- Shares outstanding
- 73.35M
- Employees
- 4,880
- Next earnings
- —
About Fagron NV
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
- ISIN
- BE0003874915
- Founded
- 1990
- Listed since
- Oct 5, 2007
- Exchange
- Euronext Brussels
- Currency
- EUR
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Guangzhou Kingmed Diagnostics Group Co., Ltd.SHSE: 603882 | $1.96B | CN¥28.82 | -0.83% |
| Astrana Health, Inc.NasdaqCM: ASTH | $1.92B | $38.24 | +1.84% |
| Huaxia Eye Hospital Group Co.,Ltd.SZSE: 301267 | $1.88B | CN¥15.16 | +0.66% |
| Dian Diagnostics Group Co.,Ltd.SZSE: 300244 | $1.86B | CN¥20.40 | -0.58% |
| emeis Société anonymeENXTPA: EMEIS | $1.80B | €9.94 | -1.09% |
| Surgery Partners, Inc.NasdaqGS: SGRY | $1.80B | $13.92 | +0.22% |
| Extendicare Inc.TSX: EXE | $1.78B | CA$26.66 | -5.76% |
| Tibet Rhodiola Pharmaceutical Holding Co.SHSE: 600211 | $1.75B | CN¥36.78 | +1.71% |
Figures last refreshed Oct 11, 2026.